Sinovac and LG form global vaccine collaboration

Sinovac and LG began meeting in March 2005 to discuss and establish their mutual interests in the commercial vaccine industry. As a result of subsequent meetings and discussions, both companies signed a letter of intent to pursue collaborative opportunities in three major areas: LG’s international marketing of Sinovac’s hepatitis A vaccine (Healive), Sinovac introducing LG’s HepB vaccines into China, and jointly working on Sinovac’s influenza vaccine (Anflu).

As per the agreement, LG will prepare a plan to market Sinovac’s Healive in the global market. Sinovac will assist this effort by providing LG with the status of registration dossiers of Healive in foreign countries. The Indian market is a likely target as LG has its own operations branch located there, with over 100 staff. Both companies will collaborate to determine the best means of supplying vaccine orders; either directly to the buyer, or through LG as a distribution agent.

Sinovac and LG also said they believe there is tremendous potential for selling LG’s HepB vaccine in China and LG is said to be “very interested” in Sinovac’s influenza vaccine.

“As an emerging company with great products, this relationship with LG is ideal,” said Sinovac president, Dr Weidong Yin. “This may propel us into the international marketplace very quickly and increase our market share in China’s vaccine market beyond our previous expectations.”